JPWO2020175629A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020175629A5 JPWO2020175629A5 JP2021502371A JP2021502371A JPWO2020175629A5 JP WO2020175629 A5 JPWO2020175629 A5 JP WO2020175629A5 JP 2021502371 A JP2021502371 A JP 2021502371A JP 2021502371 A JP2021502371 A JP 2021502371A JP WO2020175629 A5 JPWO2020175629 A5 JP WO2020175629A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- amino
- combination drug
- drug according
- oxopropane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003839 salts Chemical class 0.000 claims 12
- 229940000425 combination drug Drugs 0.000 claims 10
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 3
- 229960003603 decitabine Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960001183 venetoclax Drugs 0.000 claims 3
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 3
- -1 2-((4-cyanophenyl) amino) -4- (propylamino) pyrimidin-5-yl Chemical group 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019035668 | 2019-02-28 | ||
| PCT/JP2020/008063 WO2020175629A1 (ja) | 2019-02-28 | 2020-02-27 | 組合せ医薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2020175629A1 JPWO2020175629A1 (https=) | 2020-09-03 |
| JPWO2020175629A5 true JPWO2020175629A5 (https=) | 2022-02-09 |
Family
ID=72239685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502371A Abandoned JPWO2020175629A1 (https=) | 2019-02-28 | 2020-02-27 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210386768A1 (https=) |
| EP (1) | EP3932429A4 (https=) |
| JP (1) | JPWO2020175629A1 (https=) |
| CN (1) | CN113490512A (https=) |
| AU (1) | AU2020229558A1 (https=) |
| CA (1) | CA3131852A1 (https=) |
| TW (1) | TW202045174A (https=) |
| WO (1) | WO2020175629A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202027749A (zh) * | 2018-10-12 | 2020-08-01 | 日商富士軟片股份有限公司 | 急性骨髓性白血病用抗腫瘤劑 |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| TW202340177A (zh) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | 作為 flt3抑制劑之吡嗪化合物 |
| WO2023225005A1 (en) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| WO2025012029A1 (en) * | 2023-07-11 | 2025-01-16 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising 4-(4-methyl-piperazin-1-yl)-n-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]-1h-indazol-3-yl}-benzamide and an antineoplastic agent |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| CN102438588B (zh) | 2009-03-23 | 2015-04-01 | 埃姆比特生物科学公司 | 使用联合治疗法治疗疾病的方法 |
| PT2840080T (pt) | 2012-04-17 | 2018-02-06 | Fujifilm Corp | Composto heterocíclico que contém azoto ou sal do mesmo |
| CN105683167B (zh) | 2013-10-16 | 2018-10-23 | 富士胶片株式会社 | 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂 |
| WO2016027904A1 (ja) | 2014-08-22 | 2016-02-25 | 富士フイルム株式会社 | Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用 |
| JP6412471B2 (ja) | 2015-07-15 | 2018-10-24 | 富士フイルム株式会社 | 含窒素複素環化合物の製造方法およびその中間体 |
| TW202027749A (zh) * | 2018-10-12 | 2020-08-01 | 日商富士軟片股份有限公司 | 急性骨髓性白血病用抗腫瘤劑 |
-
2020
- 2020-02-26 TW TW109106167A patent/TW202045174A/zh unknown
- 2020-02-27 WO PCT/JP2020/008063 patent/WO2020175629A1/ja not_active Ceased
- 2020-02-27 EP EP20761500.6A patent/EP3932429A4/en not_active Withdrawn
- 2020-02-27 CA CA3131852A patent/CA3131852A1/en not_active Abandoned
- 2020-02-27 CN CN202080017172.3A patent/CN113490512A/zh active Pending
- 2020-02-27 AU AU2020229558A patent/AU2020229558A1/en not_active Abandoned
- 2020-02-27 JP JP2021502371A patent/JPWO2020175629A1/ja not_active Abandoned
-
2021
- 2021-08-27 US US17/459,412 patent/US20210386768A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020175629A5 (https=) | ||
| JP2019517487A5 (https=) | ||
| CN104918613B (zh) | 通过给予秋水仙碱衍生物治疗或预防心血管事件 | |
| JP2017504611A5 (https=) | ||
| JP2019517542A5 (https=) | ||
| JP2017530983A5 (https=) | ||
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| JP2020508338A5 (https=) | ||
| JP2016528301A5 (https=) | ||
| JP2015524472A5 (https=) | ||
| CN103298345B (zh) | 组合 | |
| CN109982699A (zh) | 一种mor激动剂与kor激动剂的药物组合物及其用途 | |
| JP2018513188A5 (https=) | ||
| JP2016185995A5 (https=) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2014528464A5 (https=) | ||
| JP2009532438A5 (https=) | ||
| JP2009511450A5 (https=) | ||
| JP2006518731A5 (https=) | ||
| JP2019515909A5 (https=) | ||
| JP2016503399A5 (https=) | ||
| JP2021535147A5 (https=) | ||
| JP2021500334A5 (https=) | ||
| JP2019218379A5 (https=) | ||
| JPWO2021187548A5 (https=) |